EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Safety and Efficacy of the First Subcutaneous ICI , Envafolimab, in the Treatment of Advanced Lung Cancer Patients: A Real‐World Study

Zixuan Dou, Li Wang, Meng Rui, Yulong Yang, Yunzhi Zhou, JieLi Zhang, Qiuhong Zhao, Mengzhao Wang, Hanping Wang iD, Xiaotong Zhang iD, Xiaoxia Cui iD, Xiaoyan Si iD und 1 weitere

Thoracic Cancer · 2025

DOI: 10.1111/1759-7714.70101 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Thoracic Cancer, 2025. Verfasst von Zixuan Dou und 12 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Tsinghua Medicine, Tsinghua University, Beijing, China. Hauptthemen laut MEDLINE: Lung Neoplasms, Immune Checkpoint Inhibitors, Antibodies, Monoclonal, Humanized, Carcinoma, Non-Small-Cell Lung. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Beijing Bethune Charitable Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Envafolimab is a novel immune checkpoint inhibitor (ICI) with several advantages due to its subcutaneous administration. Phases I and II randomized controlled trials have demonstrated promising efficacy in treating colorectal and gastric cancer. However, the safety and efficacy of Envafolimab in patients with advanced lung cancer remain to be investigated.

Methods

This retrospective, multicenter, open‐label, single‐arm cohort study examined real‐world medical data from patients treated at four medical centers to assess the safety and efficacy of Envafolimab in treating patients with advanced lung cancer. The primary safety outcome was Envafolimab‐related treatment‐emergent adverse events (TEAEs) and immune‐related adverse events (irAEs). The primary efficacy outcomes included overall survival (OS) and progression‐free survival (PFS). Then, the relationship between clinical parameters and prognosis was investigated using univariate and multivariate regression analyses. Furthermore, the impact of tumor EGFR driver mutation status and PD‐L1 expression on prognosis was explicitly explored in patients with nonsmall‐cell lung cancer (NSCLC).

Results

The cohort comprised 58 patients with a median follow‐up time of 8.3 months (from March 1, 2022, to March 7, 2024). Envafolimab‐related TEAEs and irAEs were observed in 53.4% and 27.6% of patients, respectively. No specific clinical factors were identified as being associated with irAEs. The median OS was 8.5 months (95% confidence interval [CI] 6.2–10.8), and the median PFS was 6.1 months (95% CI 3.8–8.3). For 47 patients with NSCLC, factors including ECOG PS > 2 (HR: 2.91, p = 0.015), Stage IV tumor (HR: 3.43, p = 0.043), and nonfirst‐line Envafolimab treatment (HR: 3.27, p = 0.026) were associated with poor prognosis.

Conclusion

Envafolimab demonstrates a tolerable safety profile and favorable efficacy. With its subcutaneous formulation, Envafolimab shows promising potential for treating advanced lung cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsImmune Checkpoint InhibitorsAntibodies, Monoclonal, HumanizedCarcinoma, Non-Small-Cell LungHumansMaleFemaleMiddle AgedAgedRetrospective StudiesPrognosisAdultAged, 80 and overTreatment Outcome

Stichwörter der Autor:innen

Envafolimabadvanced lung cancerimmune checkpoint inhibitorimmunotherapysubcutaneous injection

Substanzen

Immune Checkpoint InhibitorsAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • School of Medicine, Tsinghua Medicine, Tsinghua University, Beijing, China.
  • Department of Respiratory and Critical Care Medicine, Hebei Yanda Hospital, Langfang, China.
  • Department of Respiratory and Critical Care Medicine, Emergency General Hospital, Beijing, China.
  • Beijing Aerospace General Hospital, Beijing, China.
  • Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.

ORCID-Profile: Hanping Wang, Xiaotong Zhang, Xiaoxia Cui, Xiaoyan Si

Förderung

  • Beijing Bethune Charitable Foundation

Zitieren

APA

Dou, Z., Wang, L., Rui, M., Yang, Y., Zhou, Y., Zhang, J., Zhao, Q., Wang, M., Wang, H., Zhang, X., Cui, X., Si, X., & Zhang, L. (2025). Safety and Efficacy of the First Subcutaneous ICI , Envafolimab, in the Treatment of Advanced Lung Cancer Patients: A Real‐World Study. Thoracic Cancer. https://doi.org/10.1111/1759-7714.70101

Vancouver

Dou Z, Wang L, Rui M, Yang Y, Zhou Y, Zhang J, et al. Safety and Efficacy of the First Subcutaneous ICI , Envafolimab, in the Treatment of Advanced Lung Cancer Patients: A Real‐World Study. Thoracic Cancer. 2025. doi:10.1111/1759-7714.70101

BibTeX
@article{Dou2025,
  author = {Dou, Zixuan and Wang, Li and Rui, Meng and Yang, Yulong and Zhou, Yunzhi and Zhang, JieLi and Zhao, Qiuhong and Wang, Mengzhao and Wang, Hanping and Zhang, Xiaotong and Cui, Xiaoxia and Si, Xiaoyan and Zhang, Li},
  title = {Safety and Efficacy of the First Subcutaneous ICI , Envafolimab, in the Treatment of Advanced Lung Cancer Patients: A Real‐World Study},
  journal = {Thoracic Cancer},
  year = {2025},
  doi = {10.1111/1759-7714.70101}
}
Kostenlos starten →